Enhanced oral bioavailability of nevirapine within micellar nanocarriers compared with Viramune®

Colloids and Surfaces B: Biointerfaces

Volumn 122, Issue , 2014, Pages 56-65

  Moretton, Marcela A ^a   Cohen, Laura ^a   Lepera, Leandro ^a   Bernabeu, Ezequiel ^a   Taira, Carlos ^a,b   Höcht, Christian ^a   Chiappetta, Diego A ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Science Research Council CONICET   (Argentina)

Author keywords

In vivo oral pharmacokinetic studies; Nevirapine; PEO PPO PEO block copolymers; Polymeric micelles

Indexed keywords

BIOCHEMISTRY; BLOCK COPOLYMERS; CATALYST ACTIVITY; DYNAMIC LIGHT SCATTERING; POLYETHYLENE OXIDES; POLYMERS; PROPYLENE; SOLUBILITY; SYSTEM STABILITY; TRANSMISSION ELECTRON MICROSCOPY;

NEVIRAPINE; ORAL BIOAVAILABILITIES; PEO-PPO-PEO; PHARMACOKINETIC STUDIES; POLYETHYLENE GLYCOL 400; POLYMERIC MICELLE; SOLUBILIZATION CAPACITIES; UV SPECTROPHOTOMETRY; NANO-CARRIERS;

MICELLES;

COPOLYMER; GLYCEROL; MACROGOL; MACROGOL 400; NANOCARRIER; NEVIRAPINE; POLY(ETHYLENE OXIDE) POLY(PROPYLENE OXIDE) POLY(ETHYLENE OXIDE); PROPYLENE GLYCOL; SOLVENT; UNCLASSIFIED DRUG; POLY(ETHYLENE OXIDE) POLY(PROPYLENE OXIDE) POLY(ETHYLENE OXIDE) BLOCK COPOLYMER; DRUG CARRIER; MICELLE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRITICAL MICELLAR CONCENTRATION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DYNAMIC LIGHT SCATTERING; LIGHT SCATTERING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROPHOTOMETRY; AREA UNDER THE CURVE; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; MICELLE; ORAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; MALE; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; NEVIRAPINE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84904291194     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.06.046     Document Type: Article

References (52)

1. (accessed May 2014). http://www.who.int/mediacentre/factsheets/fs360/en/.
2. Weinberg G.A. Birth 2000, 27:199.
3. Morfaw F.L.I., Thabane L., Mbuagbaw L.C.E., Nana P.N. Syst. Rev. 2012, 1:13.
4. Nesheim S., Harris L.F., Lampe M. Curr. Opin. HIV AIDS 2013, 8:447.
5. (accessed September 2013). http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf.
6. (accessed September 2013). http://www.avert.org/motherchild.htm.
7. (accessed September 2013). http://www.avert.org/pmtct-guidelines.htm.
8. Lancet 2008, 372:300. Six Week Extended-Dose Nevirapine (SWEN) Study Team.
9. Chiappetta D.A., Hocht C., Sosnik A. Curr. HIV Res. 2010, 8:223.
10. Bowles A., Keane J., Ernest T., Clapham D., Tuleu C. Int. J. Pharm. 2010, 395:37.
11. L'homme R., Warris A., Burger D. Curr. Opin. HIV AIDS 2007, 2:405.
12. Lindenberg M., Kopp S., Dressman J.B. Eur. J. Pharm. Biopharm. 2004, 58:265.
13. Stieger N., Caira M.R., Liebenberg W., Tiedt L.R., Wessels J.C., De Villiers M.M. Crystal Growth Des. 2010, 10:3859.
14. Chadha R., Arora P., Saini A., Jain D.S. AAPS PharmSciTech 2010, 11:1328.
15. Rexroad V.E., Parsons T.L., Hamzeh F.M., Li X., Dreyfuss M.L., Stamper P.D., Gray R.H. J. Acquir. Immune Defic. Syndr. 2006, 43:373.
16. Buontempo F., Bernabeu E., Glisoni R.J., Quiroga E., Bregni C., Chiappetta D.A. Farm. Hosp. 2010, 34:293.
17. Chadha R., Arora P., Gupta S., Jain D.S. J. Therm. Anal. Calorim. 2011, 105:1049.
18. Lokamatha K.M., Bharathi A., Shanta Kumar S.M., Rama Rao N. Int. J. Pharm. Pharm. Sci. 2010, 2:169.
19. Sharma M.C., Sharma S. Int. J. PharmTech Res. 2011, 3:144.
20. Chudasama A., Patel V., Nivsarkar M., Vasu K., Shishoo C. Int. J. PharmTech Res. 2011, 3:1159.
21. Chiappetta D.A., Alvarez-Lorenzo C., Rey-Rico A., Taboada P., Concheiro A., Sosnik A. Eur. J. Pharm. Biopharm. 2010, 76:24.
22. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Biomaterials 2011, 32:2379.
23. Moretton M.A., Höcht C., Taira C., Sosnik A. Nanomedicine (Lond) 2014, 10.2217/nnm.13.154.
24. Chiappetta D.A., Sosnik A. Eur. J. Pharm. Biopharm. 2007, 66:303.
25. Nivaggioli T., Tsao B., Alexandridis P., Hatton T.A. Langmuir 1995, 11:119.
26. Kadam Y., Yerramilli U., Bahadur A., Bahadur P. Colloids Surf. B 2011, 83:49.
27. Dong J., Chowdhry B.Z., Leharne S.A. Colloids Surf. A 2003, 212:9.
28. He W., Fan L.F., Du Q., Xiang B., Li C.L., Bai M., Chang Y.Z., Cao D.Y. Chem. Pharm. Bull. 2009, 57:122.
29. Aimone L.D. Curr. Protoc. Pharmacol. 2005, 30:1.
30. Liu T., Xu G., Gong H., Pang J., He F. Langmuir 2011, 27:9253.
31. Jain P., Yalkowsky S.H. Int. J. Pharm. 2007, 342:1.
32. Oliveira C.P., Ribeiro M.E.N.P., Ricardo N.M.P.S., de T.V., Souza P., Lima Moura C., Chaibundit C., Yeates S.G., Nixon K., Attwood D. Int. J. Pharm. 2011, 421:252.
33. Ricardo N.M.P.S., Ricardo N.M.P.S., de F., Costa M.L.L., Bezerra F.W.A., Chaibundit C., Hermida-Merino D., Greenland B.W., Burattini S., Hamley I.W., Keith Nixon S., Yeates S.G. J. Colloid Interface Sci. 2012, 368:336.
34. Sanan R., Mahajan R.K. Colloids Surf. A 2013, 433:145.
35. Nayak A.K., Panigrahi P.P. ISRN Phys. Chem. 2012, 2012:1.
36. Sarkar B., Ravi V., Alexandridis P. J. Colloid Interface Sci. 2013, 390:137.
37. Gonzalez-Lopez J., Alvarez-Lorenzo C., Taboada P., Sosnik A., Sandez-Macho I., Concheiro A. Langmuir 2008, 24:10688.
38. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Nanomedicine 2010, 5:11.
39. Sathesh Babu P.R., Subrahmanyam C.V.S., Thimmasetty J., Manavalan R., Valliappan K., Kedarnath S.A. Dhaka University J. Pharm. Sci. 2008, 7:119.
40. Crothers M., Ricardo N.M.P.S., Heatley F., Nixon S.K., Attwood D., Booth C. Int. J. Pharm. 2008, 358:303.
41. Kulthe S.S., Inamdar N.N., Choudhari Y.M., Shirolikar S.M., Borde L.C., Mourya V.K. Colloids Surf. B 2011, 88:691.
42. Gaucher G., Satturwar P., Jones M.-C., Furtos A., Leroux J.-C. Eur. J. Pharm. Biopharm. 2010, 76:147.
43. Yu H., Xia D., Zhu Q., Zhu C., Chen D., Gan Y. Eur. J. Pharm. Biopharm. 2013, 85:1325.
44. Bromberg L.E., Ron E.S. Adv. Drug Deliv. Rev. 1998, 31:197.
45. Qian S., Wong Y.C., Zuo Z. Int. J. Pharm. 2014, 10.1016/j.ijpharm.2014.04.015.
46. Plotkin M., Vaibavi S.R., Rufaihah A.J., Nithya V., Wang J., Shachaf Y., Kofidis T., Seliktar D. Biomaterials 2014, 35:1429.
47. Zhang W., Shi Y., Chen Y., Hao J., Sha X., Fang X. Biomaterials 2011, 32:5934.
48. Chen L., Sha X., Jiang X., Chen Y., Ren Q., Fang X. Int. J. Nanomed. 2013, 8:73.
49. Handbook of Pharmaceutical Excipients 2009, Pharmaceutical Press and American Pharmacists Association, London-Chicago. 6th ed. R.C. Rowe, P.J. Sheskey, M.E. Quinn (Eds.).
50. (accessed May 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/03/WC500163989.pdf.
51. (accessed May 2014). http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm.
52. (accessed May 2014). http://www.fda.gov/.